Chronic treatment with losartan (angiotensin II type 1 receptor antagonist) normalizes enhanced acetylcholine-induced coronary vasoconstriction in isolated perfused hearts of type 2 diabetic OLETF rats

J Smooth Muscle Res. 2009 Oct;45(5):197-208. doi: 10.1540/jsmr.45.197.

Abstract

We previously reported that isolated perfused hearts from streptozotocin (STZ)-induced diabetic rats exhibited increases in the sensitivity of the coronary vasoconstriction induced by acetylcholine (ACh) infusion (versus age-matched controls) (Kamata et al., 2008). Here, we examined the ACh-induced coronary vasoconstriction in perfused hearts taken from Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a type 2 diabetes model, at the chronic stage of diabetes (38-40 weeks old). The ACh-induced vasoconstriction was greatly enhanced in such rats [versus age-matched control Long-Evans Tokushima Otsuka (LETO) rats]. This enhancement was improved by the chronic administration of the angiotensin II type I receptor (AT(1)-receptor) antagonist losartan (25 mg kg(-1), p.o., for 4 weeks). Further, the enhancement of the ACh-induced vasoconstriction seen in the OLETF group was suppressed by tempol, a superoxide dismutase mimetic. These results suggest that the coronary artery contractile response to ACh is enhanced in type 2 diabetic OLETF rats, and that this enhancement may be attributable to increased AT(1) receptor-mediating signaling and/or to increased oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Animals
  • Coronary Vessels / drug effects
  • Cyclic N-Oxides / pharmacology
  • Diabetes Mellitus, Type 2 / physiopathology*
  • In Vitro Techniques
  • Losartan / pharmacology*
  • Male
  • Rats
  • Rats, Inbred OLETF
  • Spin Labels
  • Vasoconstriction / drug effects*

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Cyclic N-Oxides
  • Spin Labels
  • Losartan
  • Acetylcholine
  • tempol